Search hospitals > California > Fresno
Kaiser Permanente-Fresno
Claim this profileFresno, California 93720
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
150 reported clinical trials
6 medical researchers
Summary
Kaiser Permanente-Fresno is a medical facility located in Fresno, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Kaiser Permanente-Fresno is involved with conducting 150 clinical trials across 317 conditions. There are 6 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Natalya Greyz-Yusupov.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Jennifer M. SugaKaiser Permanente-Oakland1 year of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
33 reported clinical trials
97 drugs studied
Samantha A. SeawardKaiser Permanente Medical Center - Santa Clara2 years of reported clinical research
Studies Cancer
Studies Breast Cancer
22 reported clinical trials
63 drugs studied
Tatjana Kolevska, MDKaiser Permanente-Vallejo7 years of reported clinical research
Studies Skin Cancer
Studies Melanoma
20 reported clinical trials
51 drugs studied
Natalya Greyz-YusupovKaiser Permanente-Fresno4 years of reported clinical research
Studies Cancer
Studies Breast Cancer
5 reported clinical trials
10 drugs studied
Clinical Trials running at Kaiser Permanente-Fresno
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Cancer
Squamous Cell Carcinoma
Follicular Lymphoma
Ovarian Cancer
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Kaiser Permanente-Fresno?
Kaiser Permanente-Fresno is a medical facility located in Fresno, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Kaiser Permanente-Fresno is involved with conducting 150 clinical trials across 317 conditions. There are 6 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Natalya Greyz-Yusupov.